Search Results

264 Results for "recursion".

Sort By

Layoffs

Recursion Downsizes by 20% To Boost Cash Position

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027.

June 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025
·
16 min read
Press Releases

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

July 9, 2025
·
5 min read
Press Releases

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

September 4, 2025
·
4 min read
Press Releases

Recursion to Participate in Upcoming Investor Conference

April 1, 2025
·
1 min read
Neuroscience

Recursion Reports Thin Mid-Stage Efficacy Data for Rare Brain Disease Therapy

Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine the need for an additional study.

September 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025
·
20 min read
Press Releases

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

March 3, 2025
·
19 min read
Business

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, reported business updates and financial results for its first quarter ending March 31, 2024.

May 9, 2024
·
15 min read
Business

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Recursion announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.

April 16, 2024
·
5 min read